IL-4 and TNF induce mAb 6G10-recognized expression on bone marrow stromal cells
US5206345A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 2, 1990 |
| Grant date | Apr 27, 1993 |
| Priority date | — |
| Expiry date | Aug 2, 2010 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/7055
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An improved method of screening a cell line for the production of a binding partner that binds with a cell-surface molecule, by contacting the binding partner with IL4-activated and nonactivated human bone marrow stromal cells, and selecting binding partners that bind to the IL4-activated human bone marrow stromal cells but not to the nonactivated human bone marrow stromal cells. The selected binding partners may thereafter be tested for the ability to block CD34.sup.+ bone marrow cell binding to IL4-activated human bone marrow stromal cells. The binding partners are preferably also characterized by binding to human VCAM-1. A representative embodiment is mAb 6G10 produced by hybridoma ATTC No. HB 10519.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.